Short Stature Assessment in Children
This case-based enduring activity will cover the diagnosis, treatment and management of children with growth/growth hormone disorders.
This continuing education activity is administered by the National Association of Pediatric Nurse Practitioners (NAPNAP) as an Agency providing continuing education credit. Individuals who complete this program and earn a 70% or higher score on the post test will be awarded 1.0 NAPNAP contact hours, of which 0.25 is pharmacology content.
Supported by an Educational Grant from Novo Nordisk.
There is no fee to participate in this activity.
Participants are forbidden to reproduce, republish, redistribute, or resell this course in any other form. For copyright-related questions, please email your question to: email@example.com.
Copyright 2016 © by Med Learning Group.
Pediatric-focused advanced practice registered nurses
1. Review methods to measure and plot height; and calculate height velocity and midparental target height to allow early diagnosis of growth disorders in pediatric patients
2. Identify diagnostic criteria that allow to differentiate causes of growth deficiency
3. Identify tools for better communication with patients and families and coordination of multidisciplinary care
4. Discuss challenges in the referral to specialists for the diagnosis of growth hormone deficiency or other diseases responsible for short stature and their appropriate management
Jan M. Foote, DNP, ARNP, CPNP, Pediatric Nurse Practitioner, Blank Children’s Endocrinology Clinic, Des Moines, IA; Adjunct Clinical Associate Professor, College of Nursing, The University of Iowa, Iowa City, IA
Mitchell E. Geffner, MD, Chief of the Center for Endocrinology, Diabetes, and Metabolism, Children's Hospital Los Angeles; Professor of Pediatrics, Keck School of Medicine, University of Southern California, Los Angeles, CA
Course Chair - Dr. Foote has research contracts with Endo Pharmaceuticals and Novo Nordisk. She is on the Speaker’s Bureau for Genentech and Abbvie and also received an honorarium from Novo Nordisk as a co-author of a CME newsletter.
Faculty - Dr. Geffner receives research grant funding from Eli Lilly Inc. and has research contracts with Novo Nordisk and Versartis. He is also a clinical trial consultant for Daiichi-Sankyo, receives royalties from McGraw-Hill and UpToDate, and serves on Advisory Boards for Ipsen, Pfizer, Inc., and Sandoz, and on the Data Safety Monitoring Board for Tolmar. He has also served as a lecturer for Sandoz.
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During the course of this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
- 1.00 Contact hours